Miaozhen Qiu

26PUBLICATIONS
32CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Cancer geneticsTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (26)

|Jul 21, 2026
Clinical benefit of PD-1 antibody plus chemotherapy in advanced HER2 negative gastric or gastro-oesophageal junction adenocarcinoma according to PD-L1 levels: Post-hoc analysis of RATIONALE-305 and pooled analysis of individual patient-level data.

|Jul 16, 2025
The antibody-drug conjugate SHR-A1904 for targeting CLDN18.2 in advanced gastric or gastroesophageal junction cancer: a phase 1 trial.

Dan-Yun Ruan, Hao-Xiang Wu, Su-Xia Luo

|May 30, 2025
Tebotelimab plus niraparib in previously treated locally advanced or metastatic solid tumors: A phase 1b dose escalation and expansion study.

Miao-Zhen Qiu, Hongming Pan, Ka On Lam

|Dec 15, 2024
Addition of SHR-1701 to first-line capecitabine and oxaliplatin (XELOX) plus bevacizumab for unresectable metastatic colorectal cancer.

Miao-Zhen Qiu, Yuxian Bai, Jufeng Wang

|Dec 31, 2023
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023.

Feng-Hua Wang, Xiao-Tian Zhang, Lei Tang

|Sep 21, 2023
Dynamic single-cell mapping unveils Epstein‒Barr virus-imprinted T-cell exhaustion and on-treatment response.

Miao-Zhen Qiu, Chaoye Wang, Zhiying Wu

Pageof 5

Frequent Collaborators

12 joint publications

Rui-Hua Xu

4 joint publications

Zhao-Lei Zeng

3 joint publications

Hui-Yan Luo

2 joint publications

Yu-Hong Li